The Spanish Association of Cancer Research recognizes his work and grants him the ASEICA Young Investigator Award 2018.
The award ceremony will be held in Valencia on 6, 7 and 8 November.
The Spanish Association for Research on Cancer (ASEICA) has announced the winners of the 2018 ASEICA Awards, among them Roger Gomis, head of the Growth Control and Metastasis lab at IRB Barcelona, who has received the Young Investigator Award in acknowledgement of his work on cancer.
ICREA researcher Roger Gomis leads a multidisciplinary lab devoted to metastasis research at IRB Barcelona. His work focuses on the identification and functional validation of the mechanisms that allow breast and colon cancer to metastasize to clinically relevant sites, and he has published various important articles in recent years.
“These awards aim to acknowledge the magnificent work that Spanish scientists are doing in spite of insufficient resources in the country,” said Carlos Camps, president of ASEICA.
The projects of the awardees will be presented in Valencia on 6,7 and 8 November in a gathering that will serve to disseminate advances in cancer research, present the most recent studies in the field, and showcase the work being undertaken on different types of tumour.
More information: http://www.aseica.es/
An understanding of the molecular basis of differences in the incidence and survival of cancer between men and women may allow the discovery of specific and more effective treatments.
The study, published in Science Advances, compares the brain tumours of male and female flies at the molecular level and identifies proteins responsible for the different degree of aggressiveness.
The radio station COPE, the newspaper ABC, RTVE and the scientific news agency SINC, among other media, have echoed news about a study led by Xavier Salvatella, head of the Molecular Biophysics Laboratory at IRB Barcelona. This study indicates that chaperone protein Hps70 could be an attractive therapeutic target for the treatment of Kennedy’s disease, a rare neuromuscular disorder, as well as castration-resistant prostate cancer.
Activation of the chaperone protein Hsp70 leads to a decrease in the formation of androgen receptor aggregates, which give rise to muscular atrophy in patients with Kennedy´s disease, a rare condition for which no treatment is available.
The results may also be useful in the search for a treatment for castration-resistant prostate cancer, a disease that causes 30,000 death a year in Europe and for which there is no treatment.
The study, which has been published in Nature Communications, is a collaboration with the University of California San Francisco and the University of Michigan.
